TFAP2E-DKK4 and chemoresistance in colorectal cancer

New England Journal of Medicine

Volumn 366, Issue 1, 2012, Pages 44-53

  Ebert, Matthias P A ^a   Tan̈zer, Marc ^b   Balluff, Benjamin ^b,d   Burgermeister, Elke ^a   Kretzschmar, Antje Karen ^b   Hughes, David J ^j   Tetzner, Reimo ^k   Lofton Day, Catherine ^l   Rosenberg, Robert ^b   Reinacher Schick, Anke C ^e   Schulmann, Karsten ^e   Tannapfel, Andrea ^f   Hofheinz, Ralf ^a   Roc̈ken, Christoph ^g   Keller, Gisela ^b   Langer, Rupert ^b   Specht, Katja ^b   Porschen, Rainer ^h   Stoḧlmacher Williams, Jan ⁱ   Schuster, Tibor ^b,c   Strob̈el, Philipp ^a   Schmid, Roland M ^b   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h Bremen Ost Hospital   (Germany)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^k EPIGENOMICS AG   (Germany)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; DICKKOPF 4 PROTEIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GLYCOPROTEIN; IRINOTECAN; OXALIPLATIN; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2 EPSILON; UNCLASSIFIED DRUG; DKK4 PROTEIN, HUMAN; DNA; SIGNAL PEPTIDE; TFAP2E PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; COHORT ANALYSIS; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DKK4 GENE; DNA METHYLATION; DRUG METABOLISM; EFFECT SIZE; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; METHYLATION; MICROSATELLITE INSTABILITY; MONOTHERAPY; PLASMID; PREDICTION; PRIORITY JOURNAL; RECTUM CANCER; TFAP2E GENE; TREATMENT RESPONSE; TUMOR GENE; UNSPECIFIED SIDE EFFECT; AGED; CHEMORADIOTHERAPY; COLORECTAL TUMOR; DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; TUMOR CELL LINE;

AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DNA; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; TRANSCRIPTION FACTOR AP-2;

EID: 84855755065     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1009473     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
3. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
4. Weichert W, Röske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008;14:1669-77. (Pubitemid 351469450)
5. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. Genome Biol 2005;6:246.
6. Giaretti W, Molinu S, Ceccarelli J, Prevosto C. Chromosomal instability, aneuploidy, and gene mutations in human sporadic colorectal adenomas. Cell Oncol 2004;26:301-5. (Pubitemid 40916731)
7. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
8. Rosenberg R, Nekarda H, ZimmermannF, et al. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. J Surg Oncol 2008; 97:8-13.
9. Ebert MP, Model F, Mooney S, et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 2006; 131:1418-30. (Pubitemid 44708938)
10. Wojdacz TK, Dobrovic A, Hansen LL. Methylation-sensitive high-resolution melting. Nat Protoc 2008;3:1903-8.
11. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248-57.
12. Prix L, Uciechowski P, Böckmann B, Giesing M, Schuetz AJ. Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool. Clin Chem 2002;48:428-35. (Pubitemid 34174576)
13. Xi Y, Formentini A, Nakajima G, Kornmann M, Ju J. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncol Rep 2008;19:257-62. (Pubitemid 351176158)
14. Xi Y, Nakajima G, Schmitz JC, Chu E, Ju J. Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics 2006;7:68.
15. Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:4217-23. (Pubitemid 47548561)
16. Dalgin GS, Drever M, Williams T, King T, DeLisi C, Liou LS. Identification of novel epigenetic markers for clear cell renal cell carcinoma. J Urol 2008;180:1126-30.
17. Orso F, Fassetta M, Penna E, et al. The AP-2alpha transcription factor regulates tumor cell migration and apoptosis. Adv Exp Med Biol 2007;604:87-95.
18. Maeda S, Tsukada S, Kanazawa A, et al. Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus. J Hum Genet 2005;50:283-92. (Pubitemid 41159984)
19. Woodfield GW, Horan AD, Chen Y, Weigel RJ. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res 2007;67:8439-43. (Pubitemid 47437415)
20. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K. Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res 2007; 13:6115-21. (Pubitemid 350075070)
21. Chung W, Kwabi-Addo B, Ittmann M, et al. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS ONE 2008;3(4):e2079.
22. Maehata T, Taniguchi H, Yamamoto H, et al. Transcriptional silencing of Dickkopf gene family by CpG island hypermethylation in human gastrointestinal cancer. World J Gastroenterol 2008;14: 2702-14.
23. You J, Nguyen AV, Albers CG, Lin F, Holcombe RF. Wnt pathway-related gene expression in inflammatory bowel disease. Dig Dis Sci 2008;53:1013-9. (Pubitemid 351379836)
24. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7.
25. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42. (Pubitemid 46631407)
26. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9. (Pubitemid 351171687)